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There is no consensus on the optimal length of stay and timing of release from hospital in patients admitted with
acute asthma. We hypothesize that it might be safe to discharge patients from hospital once they have responded
clinically to intensive anti-asthma treatment.
In a non-randomized prospective controlled study, we compared two discharge protocols in consecutive patients
admitted for acute severe exacerbations of bronchial asthma. Patients in group A were discharged after remission of
signs and symptoms and those in group B after improvement but before complete remission of signs and symptoms.
Peak expiratory flow rates (PEFR) were monitored but were not used as discharge criteria for either group. Patients
with complicating disease and who were likely to be non-compliant were excluded.
The length of hospital stay (LOS) and best PEFR at discharge were significantly lower in group B (87 admissions)
than group A (80 admissions). The mean (+SD) LOS was 1?8(+1) days vs. 3?5(+1?4) days and best PEFR was
58(+17)% predicted versus 71(+15)% predicted respectively (P 5 0?001 for both variables). No patient in either
group relapsed within 4 weeks of discharge from hospital.
We concluded that the release of asthmatics who respond promptly to intensive treatment and are compliant with
medication despite incomplete resolution of symptoms, signs and PEFR at the time of discharge from hospital may
not be associated with increased risk of early relapse.
Key words: severe asthma; acute exacerbations; hospitalization; length of stay; relapse; peak expiratory flow rate;
guidelines.
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Admission to hospital is an important event in the natural
history of bronchial asthma. It signifies a severe exacerba-
tion of disease and failure of both long-term control and
acute crisis intervention. Even a single hospitalization is
indicative of severe disease (1) and a risk factor for
subsequent exacerbations (1), hospital re-admissions (2,3)
and death from asthma (2,4,5,6,7). In terms of the global
economic burden of asthma, it has been estimated that
hospitalization accounts for about half of the total direct
costs [(45% in Singapore for 1992 (8) and 55% in the
U.S.A. for 1987 (9)] and is associated with considerable
indirect costs from loss of economic productivity.
The focus of most asthma management guidelines is,
therefore, to prevent acute exacerbations and minimizeReceived 23 May 2000 and accepted in revised form 28 September
2000.
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0954-6111/00/121234+07 $35?00/0hospitalization in order to reduce morbidity and overall
costs. Less attention however has been paid to optimizing
the duration of hospitalization itself (10). It is conventional
practice to release patients from hospital only after near
complete remission of the signs and symptoms of asthma.
There is no consensus however in current asthma guidelines
on the point in time during recovery from an acute
exacerbation when patients may be released from hospital
(11,12).
The guidelines published by the United States National
Asthma Education and Prevention Program Expert Panel
(USNAEPP) in their second report in 1997 suggest that
patients may be released when ‘minimally symptomatic
from asthma and little wheeze on examination . . . which
usually corresponds to PEFR (peak expiratory flow rate) or
FEV1 70% of predicted or personal best (11). The British
Thoracic Society however had indicated that, at discharge
from hospital, the PEFR should be 4 75% of predicted or
best and PEFR diurnal variability 5 25% (12). The
recovery of pulmonary function after acute asthma is out
of phase with and often occurs later than remission of
symptoms (13,14). Thus, the application of more stringent
spirometric criteria at discharge, as recommended in the# 2000 HARCOURT PUBLISHERS LTD
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duration of hospitalization than discharge protocols based
primarily upon clinical assessment.
It is dicult, in an individual patient, to predict the
likelihood of relapse following effective treatment of acute
asthma. Moreover, there is little evidence to suggest that,
once patients have clearly recovered from the acute
symptomatic airways obstruction, either the risk of relapse
or death (15) from asthma can be reduced by longer stay in
hospital. We hypothesize therefore, that it might be safe
and effective to discharge patients from hospital once they
have responded clinically to intensive anti-asthma treat-
ment. We have conducted a controlled study of an early
discharge policy in patients hospitalized for acute sponta-
neous exacerbations of bronchial asthma.
Methods
PATIENTS
Consecutive patients above 12 years of age admitted to the
Medical Department of a university hospital with acute
exacerbations of asthma were entered into the study. All
patients had presented with acute exacerbations of symp-
toms consistent with asthma to the Emergency Department
of the hospital. Attending staff at the Emergency Depart-
ment who assessed the patients, administered initial
treatment and decided on the hospital; admission were
not informed of this study. Hospital admission, whether to
general medical or intensive care wards, was based upon the
clinical judgement of attending staff in the Emergency
Department. Following hospitalization, all patients were
attended to by respiratory specialists who confirmed the
diagnosis of asthma by documenting reversible airways
obstruction (consistent signs, symptoms and PEFR or
FEV1) either spontaneously or with treatment. We excluded
all current or ex-smokers in whom the personal best FEV1
was 5 80% of predicted. During the study periods 203
patients were admitted with acute asthma. We excluded 21
patients with intercurrent complications (usually respira-
tory tract infections which needed antibiotic treatment)
which may have prolonged stay in hospital, 24 who refused
or were deemed very unlikely to be compliant with long-
term preventive treatment and one patient who could not
be contacted after he was discharged.
Near fatal asthma (NFA) was defined as syncope,
hypercapnia (PCO24 50mmHg) and/or endotracheal in-
tubation during an acute episode of asthma exacerbation.
HOSPITAL TREATMENT OF ASTHMA
All hospitalized patients were managed by the same group
of attending physicians and received a standard intensive
regimen of anti-asthma drugs during the study periods.
Patients received 5mg of nebulized salbutamol every 6 h for
the first 12 h. Peak expiratory flow rate (PEFR) was
measured before and after each inhalation of salbutamol
using a mini-Wright PEFR meter and the best of at least
three measurements charted. Systemic corticosteroid wasadministered to all patients as intravenous hydrocortisone
200mg every 6 h for the first 12 h followed by oral
prednisolone 30– 40mg daily at 16.00 hours. Patients were
maintained on their usual dose of long acting bronchodi-
lators, either oral slow release theophyllines [Theo-Dur 200
(Astra, So¨derta¨lje, Sweden) or 300mg BD] or inhaled
salmeterol 50 mg BD [Serevent (GlaxoWellcome, Green-
ford, U.K.)].
For patients with low initial PEFR measurements
( 100mlmin71 or not measurable due to extreme breath-
lessness) who did not respond to initial treatment, the dose
interval of inhaled salbutamol was reduced to every 2 or
4 h. If they had not taken methylxanthines previously,
intravenous theophylline was administered as a slow
infusion of 0?6mg kg71h71 without a loading bolus. Serum
theophylline was measured to avoid drug toxicity, no
attempt was made to achieved optimal therapeutic levels in
all patients.
The management and disposition of patients admitted to
intensive care followed conventional practice (16) and have
been described previously (17,18).
The regular inhalation of salbutamol was switched to prn
when the patients were no longer having acute symptomatic
asthma. This usually occurred 12 to 24 h after hospitaliza-
tion. Best of three PEFR were charted every 6 h until
discharge.
STUDY DESIGN
We compared the effect of two discharge protocols on the
outcome of patients hospitalized with acute asthma in a
controlled prospective time-series study. The two protocols
were developed as a consensus among the four authors who
were respiratory specialists and instituted sequentially. The
late discharge protocol (group A) was administered from
December 1995 to September 1996 while the early discharge
protocol (group B) was administered from November 1996
to September 1997. During the two study periods, all
decisions on fitness for hospital discharge were made by one
of the four authors. In group A, which conforms to current
practice guidelines, patients were released from hospital
after complete or near-complete resolution of symptoms
and signs of asthma. The decision to release them was only
made after nebulized salbutamol had been discontinued for
at least 12 h. They were released only after they were
asymptomatic, reported no nocturnal awakening from
asthma, were not actively wheezy on physical examination
and did not shown physical signs of hyperinflation. In
group B, patients were released when they had shown
improvement (but before complete resolution) in the signs
and symptoms of asthma following initial intensive treat-
ment. This was a subjective decision based upon collabora-
tion of the patients perception and the physicians’
assessment of asthma activity. The PEFR was measured
every 4 to 6 h in all patients but was not used as a basis for
discharge from hospital in either protocol.
Upon discharge, all patients were prescribed a non-
tailing course of oral prednisolone (0?5mg kg71) at 16.00
hours for 7 days. They were maintained on their usual long-
TABLE 1. Clinical and demographic characteristics
Group A Group B
Period of study 12/95–9/96 11/96–9/97
Number of patients 77 80
Number of admissions 80 87
Number of re-admissions 3 8
Age (years) 38+16 39+16
Female:male 45:32 47:32
ICU for current admission (%) 2/80 (2?5) 5/87 (5?7)
ICUþprecious NFA (%) 4/80 (6?2) 13/87 (14?9)
ICU: number of patients managed in the intensive care
unit,
NFA: near fatal asthma (definition in Methods).
There were no significant differences between the two
groups.
TABLE 2. Length of hospital stay and best peak expiratory
flow rate at discharge
Group A Group B P-values
LOS (day) 3?5 (1?4) 1?8 (1?0) 50?0001
Best PEFR
(% predicted)
71 (15) 59 (17) 50?0001
LOS: length of hospital stay; Best PEFR: best peak
expiratory flow rate measured on the day of discharge.
FIG. 1. This figure shows the relation between length of
hospital stay and best PEFR measured on the day of
discharge in the two study groups. Within each group,
there is no significant correlation between length of
hospitalization and PEFR. *: group B; ~: group A.
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long-term preventive treatment based upon symptoms of
asthma activity in the weeks immediately preceding the
current acute exacerbation. Except for patients with mild
episodic asthma, all other patients were also prescribed a
‘stepped up’ regimen of inhaled corticosteroids similar to
current USNAEPP (11) and British Thoracic Society (12)
guidelines. The importance of drug compliance, trigger
avoidance and self-management of acute exacerbations was
discussed with each patient but no systematic education
programme or written action plan was administered.
All patients were reviewed in the outpatient clinic 4 weeks
after discharge. Patients who did not keep their appoint-
ments were contacted on the phone (none in group A and
six in group B). Relapse was defined as acute exacerbation
of asthma which required unscheduled clinic visits,
emergency room treatment or hospitalization within 4
weeks of discharge.
As an additional precaution we decided that the study
will be stopped after the first early relapse was noted in
group B. Since no patients experienced an early relapse
during the study, the early discharge protocol was
administered beyond the study period. In order to maintain
comparable group size and seasonality however, only data
from patients admitted during the pre-determined study
periods was analysed.
DATA ANALYSIS
The PEFR is expressed as % predicted (19). The data is
presented as mean+ standard deviation. We employed the
w2 (categorical values) and Student’s t-tests (continuous
variables) to examine differences between groups. The P-
values5 0?05 was taken as significant. Except for the single
patients in group B, who could not be contacted at 4 weeks,
all patients were recruited prospectively and the data
analysis was made on a ‘intention to treat’ basis.
Results
More women than men were admitted to hospital with
acute asthma in this study. The female to male ratio was
1?4. As shown in Table 1, the characteristics of the two
groups were comparable. There was a larger number of
patients with NFA in group B. This was not statistically
significant but did suggest that a relatively greater number
of high risk patients were included in group B. The
proportion of patients with low PEFR  100mlmin71 or
not measurable PEFR was comparable between the two
groups. They also had similar during of asthma, severity of
asthma symptoms and intensity (frequency of inhaled
corticosteroids and add on medication) of pre-admission
anti-asthma medication. The intensity of anti-asthma
medication during and after hospitalization were compar-
able. All patients survived their acute exacerbations and
were discharged according to the respective protocols.
On average, patients in group A stayed 1?7 days longer in
hospital than those in group B (Table 2). The best PEFR
measured on discharge was significantly higher in group Athan group B patients (Table 2 and Fig. 1). There was no
correlation however, between the length of hospital stay
and PEFR at discharge within each group (Fig. 1).
In group B, the hospitalization was less than 24 h in 15%
of admissions (13/87, Fig. 1). This subgroup of patients
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clearly responded to intensive treatment and were released
the very next day. Because the signs of airways obstruction
had usually not resolved completely at this time, similar
patients in group A would have been kept under observa-
tion for another day. In 57% (50/87) of group B, the
symptoms (usually nocturnal awakening) and/or signs
(mild wheeziness on ausculation) of asthma had not abated
completely at the point of hospital discharge. Moreover, the
best PEFR was 5 40% predicted at discharge in 15% of
cases. These patients were however fully ambulant and no
longer acutely symptomatic.
No patients in either group experience relapse of asthma
within 4 weeks of hospital discharge (Table 3). The
information on late relapse from asthma (4 4 weeks) was
incomplete since not all patients were followed up after 4
weeks. It is likely therefore, that the overall relapse rate of
7% (11/157) is an underestimate. There was no significant
difference however in late relapse from asthma between the
two groups during the period of the study (Table 3). There
were also no deaths from asthma in either group during the
study periods.
Since no early relapse was reported during the study, we
extended the early discharge protocol beyond the pre-
determined study period. The first early relapse occurred
five months later, after 125 patients had been managed
according to the experimental protocol.
Discussion
Patients on the control protocol (group A) were kept in
hospital until near complete remission of current signs and
symptoms of asthma. This is consistent with recommenda-
tions of most practice guidelines and represents the usual
standard of practice in Singapore and elsewhere (11,12).
The mean PEFR at discharge of patients in the control
group was 71% of predicted, close to that suggested by
USNAEPP guidelines (11). Their average length of stay in
hospital was 3?5 (+1?4) days. This is similar to the results
from a survey of 5267 adult inpatient-hospital days fromTABLE 3. Relapse of asthma after discharge from hospital
Group A Group B P-values
 4 weeks after
hospitalization
0 0
During study period
(per patients) (%)
3/77 (3?9) 8/80 (10) 40?1
During study period
(per admission) (%)
3/80 (3?8) 8/87 (9?2) 40?1
Not all patients were followed up after 4 weeks. Thus, the
data on late asthma relapses (44 weeks) is incomplete and
is probably an underestimate.
Relapse: defined in Methods.1990 to 1966 in two major hospitals in Singapore which
showed that, for bronchial asthma, the average length of
stay was 3?9 (+3?1) days (20). It is also comparable to the
average length of stay reported by Mayo et al. (21) of 4?0
days and Strauss et al. (22) of 3?8 (+0?4) days in North
America and by Kolbe et al. (23) of 3?7 (2?9) days in New
Zealand. Furthermore, Bailey et al. (24) have shown that
application of a clinical pathway according to current
practice guidelines actually increased the average length of
hospital stay from 3?2 (+2?3) days to 4?4 (+3?3) days.
Thus, on the average, patients hospitalized with acute
asthma require 3?5 to 4 days of intensive treatment to
achieve full clinical remission.
We found however, that patients who were released from
hospital before complete remission of signs and symptoms
(group B) did not experience a greater frequency of early
relapse than patients in whom clinical remission had
occurred (group A). This study confirms and extends the
observations of Mayo et al. (21) who reported that a
reduction of hospital stay by 0?8 days (17%) following
improvement in the process of inpatient care did incur a
higher re-admission rate. Similarly Bisgaard et al. (25), in a
national survey, reported a reduction in the average
number of hospital days per admission from 5?1 days to
3?2 days between 1978 and 1993 among children in
Denmark. This 37% reduction in length of hospitalization
was associated with a 50% reduction in the risk for
readmission (25). The average reduction in the length of
hospital stay in this study was 1?5 days and represented
over 50% reduction from controls. Furthermore, about
half the patients in group B had some clinical signs of
asthma activity at discharge and a minority (15%) had
moderate to severe airflow limitation according to usual
standards (Fig. 1, PEFR5 40% predicted). This study was
designed to test the feasibility and safety of a new
expeditious management protocol. Our results are consis-
tent with the notion that short hospital stays for asthma
may not be associated with higher risk of re-admissions
(21,25). However, this protocol is a major departure from
conventional practice and is at variance with most
consensus guidelines. It should therefore be approached
with circumspection.
Despite the lack of randomization the two study groups
were similar in terms of patient characteristics, intensity of
drug treatment, asthma activity and severity of the acute
exacerbation. Selection bias was limited by recruiting
consecutive patients (including those with NFA), conduct-
ing the study over two comparable epochs in consecutive
years and ensuring that the doctors who decided on
hospital admission were not involved in the study and
unaware that it was in progress. One hundred and fifty-
seven patients out of 203 (77%) were studied. We only
excluded patients with intercurrent infections who required
anti-microbial treatment and those who refused long-term
preventive medication. The patients in this study were
therefore representative of the majority of patients admitted
to hospital with acute asthma.
A standard drug regimen was administered by the same
group of attending respiratory specialists throughout the
study. The two management protocols were however
1238 T. K. LIM ET AL.administered sequentially in an open fashion. We were
therefore unable to eliminate completely the element of bias
in patients’ management. The main measure of patient
outcome used to assess the relative ecacy of the different
protocols in this study is the rate of early relapse.
Compliance with long-term preventive medication (espe-
cially inhaled corticosteroids) is an important determinant
of the risk of relapse following recovery from acute asthma
(26). Six patients in group B defaulted clinic follow-up and
had to be contacted by phone while another patient could
not be contacted at all. By contrast, all patients in group A
attended the clinic at 4 weeks. This suggests that overall
compliance with long-term preventive treatment was not
better (indeed it was probably worse) in group B compared
with group A patients. Thus, it is unlikely that there was a
bias which favoured patients compliance and outcome in
group B compared to controls.
The relapse rates in this study were relatively low and did
not differ between the two management protocols.
Furthermore, the good control of asthma in the 4 weeks
following discharge from hospital was achieved without a
formal educational programme or administration of
individualized action plans. This is consistent with the
observations of Cote et al. (27) that structured educational
programmes may add little to asthma control after rigorous
optimization of treatment by asthma specialists in moti-
vated patients. Similar results may not be expected in the
routine management of patients by house doctors with no
special interest in this condition.
Patients who were entered into this study had not
responded adequately to initial treatment in the emergency
department and were thus assumed to have severe and
potentially life-threatening asthma. During acute severe
asthma there may be poor correlation between clinical and
physiologic indices of airflow (13,14). Furthermore, Kiku-
chi et al. (28) have shown that some high-risk patients with
a history of near fatal asthma are unable to perceive even
severe degrees of acute airways obstruction. McFadden
et al. (29) has cautioned that insucient assessment of the
seriousness of the final episode may be an important
contributing cause of fatal asthma. They further stressed
that treatment intensity during acute illness should be
dictated by quantitative assessment rather that subjective
impressions. This was indeed the strategy adopted during
the acute intensive phase of asthma treatment in this study
(see Methods).
During the recovery phase of illness however, the role of
pulmonary function testing in determining appropriate
timing of hospital discharge is less well defined. The rate of
recovery of pulmonary function after acute asthma is highly
variable and often lags behind symptomatic recovery
(13,14,30). Different aspects of pulmonary dysfunction
may resolve at different rates. For example, the recovery
of gas exchange function may take even longer than
restitution of airway calibre and lung mechanics (31).
Interpretation of pulmonary function tests is further
complicated by the fact that increased airway lability with
wide variations in airway caliber is an inherent feature of
the recovery phase of illness (14). Moreover, studies of
patients discharged from emergency rooms following acutetreatment of spontaneous asthma exacerbations suggest
that spirometric measurements at discharge from hospital
do not reliably predict the likelihood of subsequent relapse
(32–35).
The results of this study, which suggest that it might be
safe and cost-effective to release from hospital selected
patients who had responded to intensive anti-asthma
treatment despite incomplete recovery signs, symptoms
and PEFR, should however be interpreted with caution.
This was a non-randomized study in a small number of
patients. Many key aspects of decision making were
based upon the subjective judgement of physicians with
special interest in asthma and not predefined objective
rules. There was also incomplete data on the long-term
outcome (4 4 weeks). Because of small sample size,
relatively low relapse rates and incomplete patient
follow-up, it is possible that a difference in relapses beyond
the initial 4 weeks period could have been missed in this
study.
Concern regarding risk of early relapse and asthma
death is the usual reason cited for avoiding premature
release and for keeping patients in hospital until clinical
remission. Mayo et al. (20) and Williams et al. (36)
have shown however that patients who had been dis-
charged from hospital after even sub-optimal application of
anti-asthma programmes rarely experience early relapse.
Death from asthma in this context is uncommon and
furthermore, there is little evidence that fatal asthma can be
prevented by keeping patients for longer periods in hospital
(15). The ultimate safety of an early discharge policy with
regards to mortality can only be resolved in large, multi-
centre studies. The consequences of sending patients
home with persistent airflow obstruction need further
investigation. The risk of re-exposing such patients to a
potentially hazardous home environment also needs careful
evaluation (37).
In summary, we have conducted a controlled study on
the feasibility of an early discharge protocol for patients
admitted to hospital with acute asthma. Results from a
small sample of patients suggest that this approach may
be both safe, effective and consistent with the current
emphasis on preventive treatment in bronchial asthma
(21,25,26,38–40).
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